Abstract
Chlamydia infections are common infections that are transmitted through sexual C. pneumonia is a pathogen that causes different acute and chronic infections. Due to the increase in biological knowledge and the use of more sensitive and specific techniques in the detection of the pathogen in recent years, it is thought that C. pneumonia has a role in various cardiovascular and central nervous system (CNS) diseases. There is increasing evidence that C. pneumonia may have a role in various chronic neurologic diseases, especially Alzheimer’s disease (AD) and multiple sclerosis (MS). C. pneumonia crosses the blood-brain barrier via monocytes and triggers neuroinflammation in the central nervous system. Various diagnostic methods (molecular, histopathologic, and culture) have shown the presence of C. pneumonia in patients with late-onset AD dementia. It is thought that C. pneumonia may be a cofactor in the development of MS disease by causing chronic permanent brain infection in MS patients. There are also reports of C. pneumonia causing other CNS diseases such as Guillaine Barre syndrome, encephalitis/meningoencephalitis, and cerebellar ataxia. In this section, the relationship between Chlamydia infections and neurological diseases will be discussed based on scientific research.
Keywords
- Chlamydia
- neuroinflamation
- stroke
- neurologic disease
- chlamydia infection
1. Introduction
Chlamydiae have been identified as viruses because they have a life cycle within the host cell and are smaller than bacteria. However, they were later classified as bacteria because they can also live outside the cell. With these conditions, they were named as “obligate intracellular bacteria” [1].
There are four species in the genus Chlamydia:
Chlamydia pneumonia is transmitted from person to person by direct respiratory route. The infection spreads slowly [9, 10]. It has a longer incubation period than many pathogens that cause respiratory tract disease, and this period is about a few weeks [11]. If it is within the family, the infection spreads in a shorter time [12].
Chlamydiae are obligate intracellular parasites and have a biphasic life cycle. They can grow and multiply using the host cell’s ATP. Chlamydia are in the bacteria class because they are sensitive to antibiotics, reproduce by division, contain both DNA and RNA, and have cell membranes similar to gram-negative bacteria [13, 14].
Chlamydia reproduces by forming inclusion bodies in the cytoplasm of host cells. Chlamydia pneumonia has two forms called “Elementary body” (EB) and “Reticulate body” (RB). These two forms are functionally and morphologically different from each other and undergo regular change. The EB form is the metabolically inactive, extracellular form and causes contamination. It attaches to the mucosal surfaces of the respiratory tract by inhalation and enters the host cell by endocytosis, where it transforms into the RB form.
The RB form is metabolically active and utilizes the host cell’s metabolism. It multiplies in the host cell, breaks up this cell, spreads around as newly formed elementary body bodies and continues to be transmitted. In its RB form, it is protected from the host cell’s endocytic lysosomal digestive tract, where it can be stored for years. In this way, it causes a chronic inflammatory process in the body [15, 16].
Being located intracellularly provides the ability of this bacterium to transform into a resistant form [8, 17].
In recent years, there has been a great deal of information about the physiological effects of chlamydia infection on the host cell [23]. Although it is not known exactly how
In recent years, it has been determined that
It has also been shown to cause progressive diseases with chronic inflammation processes such as lung cancer, Alzheimer’s disease, multiple sclerosis, arthritis, and atherosclerosis [18, 27, 28, 29, 30, 31].
The demonstration that various human cells (smooth muscle, monocytes, lymphocytes, macrophages, endothelium, and epithelium) are infected by
This chapter examines the potential role of chlamydial infections in different neurological diseases and the underlying mechanisms in light of the literature.
2. Chlamydial infection and cerebrovascular disease
At present, cerebrovascular diseases constitute an important public health problem because of the associated mortality and functional losses in the acute and chronic period. According to studies conducted in the USA, 500,000 new or recurrent stroke cases are observed every year [35]. Approximately 80–85% of these are cases of ischemic stroke [36, 37].
Although studies have identified many etiological factors for stroke, none of these factors can be identified in approximately 40% of cases. The number of patients with no detectable risk factors is increasing, especially in the patient population under 45 years of age [38]. The research, identification, and (if possible) treatment of potential risk factors have become a priority in order to reduce the incidence and consequences of the disease [35, 39, 40].
Many researchers have suggested that viruses play a role in the development of atherosclerosis and have shown that these pathogens are closely linked to the rapidly progressive CAD that develops in heart transplant recipients [41, 42, 43, 44, 45].
The main infectious agents implicated are
Çalık et al. investigated the presence of
Studies have generally shown that IgA antibodies are associated with ischemic cerebrovascular disease while IgG antibodies are not [49, 50, 53].
In a study by Cook et al., acute
IgG positivity is an indicator of a previous infection and can remain positive for years [11]. However, IgA antibodies have a very short half-life of 5–6 days on average. Therefore, IgA antibodies are useful in determining persistent and active carrier status. Based on observations, anti-
Acute
Although criteria have been established for the diagnosis of chronic persistent infection, a positive IgA titer is an indirect indicator that the causative pathogen is present in the body [60].
Studies have emphasized the relationship between
Schmidt et al. reported that
In summary, evidence pointing to the relationship between
3. C. pneumoniae and neurodegenerative and demyelinating diseases
Information regarding the role of
3.1 C. pneumoniae and multiple sclerosis
MS is a chronic autoimmune and demyelinating disease that affects the CNS, usually in young adults [67]. MS was first described in 1838. During the six decades following its identification, German and French physicians determined the clinical and pathological features of the disease. Previously documented only as cases, MS became one of the most common diseases in neurology at the turn of the twentieth century. The disease is characterized by damage to the myelin sheaths, oligodendrocytes, and to a lesser extent, axons and neurons. There are currently 2.5 million people with MS worldwide, and their treatment and care cost billions of dollars [68]. MS is a highly heterogeneous disease and can present with widely variable clinical signs and symptoms including motor, sensory, autonomic, and cognitive disorders, depending on the part of the CNS affected [69].
MS develops in genetically predisposed individuals as a result of a combination of environmental factors, viral or bacterial pathogens, cytokines secreted in inflammatory and autoimmune response, and other yet unidentified etiological agents. Various lesions can be seen in patients with MS, such as CNS inflammatory infiltrates, astrogliosis, demyelination, and early axonal damage [70, 71, 72].
In MS, CD4+ T helper (Th)-1 and Th17 cells perceive myelin sheath components as foreign antigens and develop an autoreaction against myelin [67].
3.1.1 Axonal and neuronal damage in MS
Inflammatory CNS damage in MS has frequently been associated with axonal damage. Although MS is classically defined as a condition primarily characterized by axonal myelin loss, axonal damage has also been described in the early pathological findings of MS lesions. Modern techniques have yielded definitive findings showing axonal damage. Antibodies to amyloid precursor proteins (APP) reveal damaged axons in the active areas of MS lesions [72].
The distinctive pathological feature of MS is demyelinating plaques, which represent areas of demyelination and gliosis around blood vessels [73]. Acute lesions show macrophage infiltration and phagocytosis of myelin membranes, as well as perivascular lymphocytes and plasma cells. The continuous destruction and regeneration of myelin has been demonstrated within progressive MS plaques [74]. Toll-like receptors (TLR) are strongly associated with many neurodegenerative and demyelinating disorders, including MS, with a significant increase in TLR expression in MS lesions. PCR studies have shown that TLR1–8 s are expressed in microglial cells obtained from MS patients [75]. In addition, healthy white matter from MS patients does not contain TLR, whereas active lesions are associated with increased TLR3 and TLR4 expression by microglia and astrocytes. Late active lesions also contain astrocytes with surface expression of TLR3 and TLR4 [75]. This indicates that early lesions are characterized by microglial infiltration, while astrocytes are also active in late active lesions. However, the exact role of TLR3 and TLR4 activation in these lesions remains unclear. TLRs have been shown to recognize highly conserved sites (pathogen-associated molecular patterns) in various microorganisms, including
Based on epidemiological observations, it has been suggested that along with genetic predisposition, exposure to an environmental factor such as an infectious agent may play a role in the pathogenesis of MS [78].
The risk of MS is increased by the presence of specific genes in the human MHC, or human leukocyte antigen (HLA) complex, on chromosome 6. In particular, HLA-DR and HLA-DQ genes, which are involved in antigen presentation, are strongly associated with the development of disease. However, although the risk of disease is higher in monozygotic than in dizygotic twins (approximately 30% and 5%, respectively), the low concurrence rate among identical twins suggests that nongenetic factors may contribute to the etiology of MS. In this regard, the etiopathogenesis of MS is complex and remains a subject of debate.
To date, about 20 microorganisms, including viruses, have been associated with MS [79]. The screening techniques used in these studies varied from serology to PCR, and the quality and number of controls examined varied greatly. The most recent pathogen associated with MS is
Sriram et al. reported the first evidence pointing to the potential role of
In recent years, the possible role of
Dong-Si et al. reported gene transcription of
In another study, active transcription of DNA of the organism indicating in a persistent and metabolically active state was detected in cultured CSF and PBMCs from MS patients but not controls [92]. Other investigators were able to culture
In contrast, a substantial number of studies from around the world have provided clear evidence that
Treatment targeting the inflammatory process is only partly effective on the course of MS. In relapsing-remitting MS, this type of therapy slows the progression of disability, while the same therapy has been shown to have little or no effect on the progression of disability in primary progressive MS. Reports regarding antimicrobial therapy in MS have also yielded conflicting results. In one trial, the antibiotic minocycline resulted in a reduction in the number of gadolinium-enhancing lesions detected by MRI [100]. Another study showed that anti-chlamydial therapy reduced brain atrophy, but showed no beneficial effect on the number of gadolinium-enhancing lesions on MRI [101].
From the data presented, there is evidence that
There are also studies showing a possible association between MS and
Finally, we cannot rule out the possibility that other pathogens could be involved in the development of MS. Viruses are often considered potential candidates because they are known to cause demyelinating disease in experimental animals and humans and are generally known to cause diseases that have prolonged latent periods and manifest clinically with relapsing and remitting symptoms [103]. However, research conducted to date has not identified any single virus that plays an important role in MS. Among the viruses proposed as MS cofactors are ubiquitous members of the Herpesviridae family, human herpesvirus 6, and Epstein-Barr virus [26]. The MS-related human retrovirus of the endogenous retrovirus family has also been identified as a potential pathogen in MS [104].
3.2 C. pneumoniae and Alzheimer’s disease
AD is among the most severe dementias and is increasing as the population ages. AD is associated with neuronal atrophy/death in certain areas of the brain and occurs in two main forms: an early-onset form that is primarily genetically determined, and late-onset AD, which is a non-familial, progressive neurodegenerative disease that is currently the most common and severe form of dementia in older adults. The descriptive neuropathology of both familial and sporadic AD includes neuritic senile plaques (NSPs), consisting mainly of amyloid-β protein, and neurofibrillary tangles (NFTs), the major component of which is modified
Viruses such as the measles virus, adenovirus, lentiviruses, and others were initially evaluated but later ruled out [112, 113]. Bacterial pathogens, including
Prions were also considered but later excluded [116].
The first article reporting an association between
AD patients included in the Balin study may have recently been exposed to
Recent studies in cultured astrocytes and microglia have shown that
In the years immediately following Balin et al.’s study, some experimental discoveries provided insight into the pathogenetic mechanisms of AD. First, there is a relationship between carriage of the APOE-4 allele and the pathobiology of
In a recent study by Chacko et al., it was shown that
The ability to infect glia is considered the key to invading the CNS via cranial neural pathways. The study by Chacko et al. demonstrated that
In addition, their study also revealed localized amyloid-β accumulation adjacent to
Thus, the secretion of amyloid-β may be a normal immune response to any microbe that might invade the nervous system, and if the infection is cleared, the accumulated amyloid-β can be cleared by phagocytic glia. However, if the bacteria are not cleared and instead become persistent or latent in neural cells, continuous amyloid-β deposition may occur, which contributes to late-onset dementia and/or accelerates amyloid-β accumulation in familial AD. In the case of
In addition to considering key pathways, it is also useful to consider changes in individual gene expression. Long-term
Because chlamydial chronic infections are characterized by a “chlamydial persistent state” inaccessible to traditional antichlamydial agents, there have been several clinical studies determining the efficacy of antibiotic therapy against
Scientific knowledge about AD and
3.3 C. pneumoniae and AIDS dementia
Many authors have investigated the possibility that
4. C. pneumoniae and other neurological complications
5. Conclusions
Thanks to the deep knowledge of
Although astrocytes, microglia, and neurons have been shown to be host cells for
Recent molecular, ultrastructural, and cultural developments have provided evidence that
Abbreviations
C | Chlamydia |
CNS | Central nervous system |
MS | Multiple sclerosis |
AD | Alzheimer’s disease |
TWAR | Chlamydia pneumoniae |
USA | United States of America |
EB | Elementary body |
RB | Reticulate body |
Hsp | Heat shock protein |
PCR | Polymerase chain reaction |
CAD | Coronary artery disease |
TNF | Tumor necrosis factor |
IL | Interleukin |
CSF | Cerebrospinal fluid |
APC | Antigen-presenting cell |
FLAIR | Fluid-attenuated inversion recovery |
MHC | Major histocompatibility complex |
APP | Amyloid precursor protein |
TLR | Toll-like receptor |
mRNA | Messenger RNA |
HLA | Human leukocyte antigen |
OND | Other neurologic diseases |
MOMP | Major outer membrane protein |
ELISA | Enzyme-linked immunosorbent assay |
PBMC | Peripheral blood mononuclear cell |
rRNA | Ribosomal RNA |
OIND | Other inflammatory neurological disease |
NIND | Non-inflammatory neurological disease |
NSP | Neuritic senile plaques |
NFT | Neurofibrillary tangles |
APOE | Apolipoprotein-E |
References
- 1.
Shor A. Chlamydia Atherosclerosis Lesion Discovery, Diagnosis and Treatment. London: Springer Science & Business Media; 2007 - 2.
Sarier M, Kukul E. Classification of non-gonococcal urethritis: A review. International Urology and Nephrology. 2019; 51 (6):901-907 - 3.
Sarier M, Sepin N, Emek M, Germen AT, Hoscan MB, Konuk E, et al. Evaluating the utility of the a.F. genital system test for pathogen diagnosis in acute male urethritis. Andrologia. 2022; 54 (4):e14377. DOI: 10.1111/and.14377. Epub 2022 Jan 22 - 4.
Sarier M, Demir M, Turgut H, Hizel A, Emek M, Kukul E, et al. New approach to microscopy of gram-stained urethral smear: The kissing slide method. Sexually Transmitted Diseases. 2020; 47 (10):712-715 - 5.
Sarıer M. Prevalence of Polymicrobial infection in urethritis. Journal of Urological Surgery. 2019; 6 (3):180-183 - 6.
Sarier M, Sepin N, Duman I, Demir M, Hizel A, Göktaş Ş, et al. Microscopy of gram-stained urethral smear in the diagnosis of urethritis: Which threshold value should be selected? Andrologia. 2018; 50 (10):e13143. DOI: 10.1111/and.13143. Epub 2018 Sep 20. PMID: 30238498 - 7.
Sarıer M, Duman İ, Göktaş Ş, Kukul E. Results of multiplex polymerase chain reaction assay to identify urethritis pathogens. Journal of urological. Surgery. 2017; 4 (1):18-22 - 8.
Kern JM, Maass V, Maass M. Molecular pathogenesis of chronic chlamydia pneumoniae infection: A brief overview. Clinical Microbiology and Infection. 2009; 15 (1):36-41 - 9.
Saikku P, Mattila K, Nieminen MS, Huttunen JK, Leinonen M, Ekman MR, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. The Lancet. 1988; 332 (8618):983-986 - 10.
Kleemola M, Saikku P, Visakorpi R, Wang SP, Grayston JT, Kleemola M. Epidemics of pneumonia caused by twar, a new chlamydia organism, in military trainees in Finland. Journal of Infectious Diseases. 1988; 157 (2):230-236 - 11.
Chou KC, Jackson LA, Ann Campbell L, Thomas Grayston J. Chlamydia pneumoniae (TWAR). Clinical Microbiology Reviews. 1995; 8 :451-461 - 12.
Mordhorst CH, Wang SP, Grayston JT. Outbreak of chlamydia pneumoniae infection in four farm families. European Journal of Clinical Microbiology & Infectious Diseases. 1992; 11 (7):617-620 - 13.
McClarty G. Chlamydiae and the biochemistry of intracellular parasitism. Trends in Microbiology. 1994; 2 (5):157-164 - 14.
Everett KDE. Chlamydia and Chlamydiales: More than meets the eye. Veterinary Microbiology. 2000; 75 (2):109-126 - 15.
AbdelRahman YM, Belland RJ. The chlamydial developmental cycle. FEMS Microbiology Reviews. 2005; 29 (5):949-959 - 16.
di Pietro M, Filardo S, Romano S, Sessa R. Chlamydia trachomatis and chlamydia pneumoniae interaction with the host: Latest advances and future prospective. Microorganisms. 2019; 7 (5):140 - 17.
Saikku P. Seroepidemiology in chlamydia pneumoniae — Atherosclerosis association. European Heart Journal. 2002; 23 (4):263-264 - 18.
Yucesan C, Sriram S. Chlamydia pneumoniae infection of the central nervous system. Curr Opin Neurol. 2001; 14 (3):355-359 - 19.
Stratton CW, Mitchell WM. The immunopathology of chlamydial infections. Antimicrobics and Infectious Diseases Newsletter. 1997; 16 (12):89-94 - 20.
Stratton CW, Sriram S. Association of Chlamydia pneumoniae with central nervous system disease. Microbes and Infection. 2003; 5 (13):1249-1253 - 21.
Palikhe A, Lokki ML, Saikku P, Leinonen M, Paldanius M, Seppänen M, et al. Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease. Clinical and Vaccine Immunology. 2008; 15 (1):55-59 - 22.
Ciervo A, Visca P, Petrucca A, Biasucci LM, Maseri A, Cassone A. Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of chlamydia pneumoniae in patients with coronary heart disease. Clinical and Diagnostic Laboratory Immunology. 2002; 9 (1):66-74 - 23.
Byrne GI. Chlamydia uncloaked. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100 (14):8040-8042 - 24.
Byrne GI, Ojcius DM. Chlamydia and apoptosis: Life and death decisions of an intracellular pathogen. Nature Reviews Microbiology. 2004; 2 (10):802-808 - 25.
Byrne GI. Chlamydia uncloaked. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100 (14):8040-8042 - 26.
Contini C, Seraceni S, Cultrera R, Castellazzi M, Granieri E, Fainardi E. Chlamydophila pneumoniae infection and its role in neurological disorders. Interdisciplinary Perspectives on Infectious Diseases. 2010; 2010 :273573 - 27.
Porritt RA, Crother TR. Chlamydia pneumoniae infection and inflammatory diseases. For Immunopathol Dis Therap. 2016; 7 (3-4):237-254 - 28.
Choroszy-Król I, Frej-Mądrzak M, Hober M, Sarowska J, Jama-Kmiecik A. Infections caused by Chlamydophila pneumoniae. Advances in Clinical and Experimental Medicine. 2014; 23 (1):123-126 - 29.
von Hertzen LC. Role of persistent infection in the control and severity of asthma: Focus on chlamydia pneumoniae. European Respiratory Journal. 2002; 19 (3):546-556 - 30.
Contini C, Grilli A, Badia L, Guardigni V, Govoni M, Seraceni S. Detection of Chlamydophila pneumoniae in patients with arthritis: Significance and diagnostic value. Rheumatology International. 2011; 31 (10):1307-1313 - 31.
Balin BJ, Gérard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, et al. Identification and localization of chlamydia pneumoniae in the Alzheimer’s brain. Medical Microbiology and Immunology. 1998; 187 (1):23-42 - 32.
Boman J, Söderberg S, Forsberg J, Slunga Birgander L, Allard A, Persson K. et al, High prevalence of chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis. 1998; 178 (1):274-277 - 33.
Evani SJ, Ramasubramanian AK. Biophysical regulation of chlamydia pneumoniae-infected monocyte recruitment to atherosclerotic foci. Scientific Reports. 2016; 6 (1):19058 - 34.
MacIntyre A, Abramov R, Hammond CJ, Hudson AP, Arking EJ, Little CS, et al. Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. Journal of Neuroscience Research. 2003; 71 (5):740-750 - 35.
Eslie L, Ronner LB, Anter ASK, Nn JOA, Anson EM. Medical progress review articles primary prevention of stroke. 1995. - 36.
Demirci, Şahin A, Üstü Y, Işık D. Serebrovasküler Hastalıklarda Önlenebilen Risk Faktörlerinin Yönetimi. Ankara Medical Journal. 2015; 15 (2) - 37.
Akpinar MB, Sahin V, Sahin N, Abacilar AF, Kiris I, Uyar IS, et al. Previous chronic cerebral infarction is predictive for new cerebral ischemia after carotid endarterectomy. Journal of Cardiothoracic Surgery. 2015; 10 (1):141 - 38.
Jose B, Duracher A. Ischemic cerebrovascular disease. In: Jose B, editor. Practical Neurology. Washington: Lipincott-Raven Publishers; 1997. pp. 379-391 - 39.
Bova IY, Bornstein NM, Korczyn. Acute infection as a risk factor for ischemic stroke. Stroke. 1996; 27 (12):2204-2206 - 40.
Uyar IS, Sahin V, Akpinar MB, Abacilar F, Okur FF, Ozdemir U, et al. Does oral hygiene trigger carotid artery intima-media thickness? Heart Surgery Forum. 2013; 16 (4):E232-E236. DOI: 10.1532/HSF98.20121137. PMID: 23958538 - 41.
Calik M, Uyar Y, Onar MK, Gunaydin M. Investigation of the relation between ischemic cerebrovascular disease and chlamydia pneumoniae infections. Turkish journal of. Cerebrovascular Diseases. 2013; 19 (2):56-63 - 42.
Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary Atherectomy. New England Journal of Medicine. 1996; 335 (9):624-630 - 43.
Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science (1979). 1994; 265 (5170):391-394 - 44.
Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: Focus on cytomegalovirus. Lancet. 1996; 348 (Suppl.1):s13-s17 - 45.
Adam E, Probtsfield JL, Burek J, Mccollum CH, Melnick JL, Petrie BL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. The Lancet. 1987; 330 (8554):291-293. 2886763 - 46.
Bandaru VCSS, Boddu DB, Laxmi V, Neeraja M, Kaul S. Seroprevalence of chlamydia pneumoniae antibodies in stroke in young. Canadian Journal of Neurological Sciences. 2009; 36 (6):725-730 - 47.
Atik B, Johnston SC, Dean D. Association of Carotid Plaque Lp-PLA2 with macrophages and chlamydia pneumoniae infection among patients at risk for stroke. PLoS One. 2010; 5 (6):e11026. DOI: 10.1371/journal.pone.0011026. PMID: 20543948; PMCID: PMC2882946 - 48.
Elkind MSV, Tondella MLC, Feikin DR, Fields BS, Homma S, di Tullio MR. Seropositivity to chlamydia pneumoniae is associated with risk of first ischemic stroke. Stroke. 2006; 37 (3):790-795 - 49.
Rai NK, Choudhary R, Bhatia R, Singh MB, Tripathi M, Prasad K, et al. Chlamydia pneumoniae seropositivity in adults with acute ischemic stroke: A case-control study. Annals of Indian Academy of Neurology. 2011; 14 (2):93-97 - 50.
Wimmer MLJ, Sandmann-Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke. 1996; 27 (12):2207-2210 - 51.
Schmidt C, Hulthe J, Wikstrand J, Gnarpe H, Gnarpe J, Agewall S, et al. Chlamydia pneumoniae seropositivity is associated with carotid artery intima-media thickness. Stroke. 2000; 31 (7):1526-1531 - 52.
Muhlestein JB. Chronic infection and coronary artery disease. Cardiol Clin. 2000; 84 (1):333-362 - 53.
Elkind MSV, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke: The northern Manhattan stroke study. Stroke. 2000; 31 (7):1521-1525 - 54.
Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke. Stroke. 2000; 31 (7):1521-1525 - 55.
Cook PJ, Honeybourne D, Lip GYH, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: The West Birmingham stroke project. Stroke. 1998; 29 (2):404-410 - 56.
Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of helicobacter pylori in human carotid atherosclerotic plaques. Stroke. 2001; 32 (2):385-391 - 57.
Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Seminars in Neurology. 1998; 18 :429-440 - 58.
Demir S. In: Demir S, editor. Virus Riketsiya ve Klamidya Hastalıkları. Vol. 1. Istanbul: Nobel Tip Kitabevi; 1996. pp. 94-115 - 59.
Birnie DH, Holme ER, McKay IC, Hood S, McColl KEL, Hillis WS. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of helicobacter pylori and other bacterial infections in increasing cardiovascular risk. European Heart Journal. 1998; 19 (3):387-394 - 60.
Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993; 87 (4):1130-1134 - 61.
Yamashita K, Ouchi K, Shirai M, Gondo T, Nakazawa T, Ito H. Distribution of chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke. 1998; 29 (4):773-778 - 62.
Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation. 1995; 92 (12):3397-3400 - 63.
Campbell LA, O’brien ER, Cappuccio AL, Kuo CC, Wang SP, Stewart D, et al. Detection of chlamydia pneumoniae TWAR in human coronary atherectomy tissues. Journal of Infectious Diseases. 1995; 172 (2):585-588 - 64.
Leinonen M. Pathogenetic mechanisms and epidemiology of chlamydia pneumoniae. European Heart Journal. 1993; 14 (Suppl K):57-61 - 65.
Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L. Increased fibrinogen levels are associated with persistent chlamydia pneumoniae infection in unstable coronary artery disease. European Heart Journal. 1998; 19 (4):570-577 - 66.
Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chlamydia pneumoniae antibodies and serum lipids in Finnish men: Cross sectional study. BMJ. 1997; 314 (7092):1456-1457 - 67.
Hafler DA, Slavik JM, Anderson DE, O’Connor KC, de Jager P, Baecher-Allan C. Multiple sclerosis. Immunological Reviews. 2005; 204 (1):208-231 - 68.
Alastair C, Christian C, Hans L, McDonald Ian R, David M, John N. In: Alastair C, editor. The Story of Multiple Sclerosis. Philadelphia: Churchill Livingstone Elsevier; 2006 3 p - 69.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. New England Journal of Medicine. 2000; 343 (13):938-952 - 70.
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology. 2000; 47 (6):707-717 - 71.
Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359 :1221-1231 - 72.
Serra Ö, Güneş A, Ferah K, Muzaffer S. Multiple Sclerosis. Akd Med J. 2017; 3 :137-147 - 73.
Barnett MH, Sutton I. The pathology of multiple sclerosis: A paradigm shift. Current Opinion in Neurology. 2006; 19 (3):242-247 - 74.
Prineas JW, Kwon EE, Cho E-S, Sharer LR. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Annals of the New York Academy of Sciences. 1984; 436 (1):11-32 - 75.
Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of toll-like receptors in the human central nervous system. Journal of Neuropathology and Experimental Neurology. 2002; 61 (11):1013-1021 - 76.
Yang X, Joyee A. Role of toll-like receptors in immune responses to chlamydial infections. Current Pharmaceutical Design. 2008; 14 (6):593-600 - 77.
Miranda-Hernandez S, Baxter AG. Role of toll-like receptors in multiple sclerosis. Am J Clin Exp Immunol. 2013; 2 (1):75-93 - 78.
Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurology. 2005; 4 :195-202 - 79.
Steiner I, Nisipianu P, Wirguin I. Infection and the etiology and pathogenesis of multiple sclerosis. Current Neurology and Neuroscience Reports. 2001; 1 (3):271-276 - 80.
Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with chlamydia pneumoniae infection of the CNS. Neurology. 1998; 50 (2):571-572 - 81.
Fainardi E, Castellazzi M, Seraceni S, Granieri E, Contini C. Under the microscope: Focus on chlamydia pneumoniae infection and multiple sclerosis. Current Neurovascular Research. 2008; 5 (1):60-70 - 82.
Stratton CW, Wheldon DB. Multiple sclerosis: An infectious syndrome involving Chlamydophila pneumoniae. Trends in Microbiology. 2006; 14 (11):474-479 - 83.
Munger KL, Peeling RW, Hernán MA, Chasan-Taber L, Olek MJ, Hankinson SE, et al. Infection with chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology. 2003; 14 (2):141-147 - 84.
Munger KL, DeLorenze GN, Levin LI, Rubertone M, Vogelman JH, Peck CA, et al. A prospective study of chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology. 2004; 62 (10):1799-1803 - 85.
Buljevac D, Verkooyen RP, Jacobs BC, Hop W, van der Zwaan LA, van Doorn PA, et al. Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients. Annals of Neurology. 2003; 54 (6):828-831 - 86.
Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infectious Diseases. 2002; 2 :11-17 - 87.
Layh-Schmitt G, Bendl C, Hildt U, Dong-Si T, Jüttler E, Schnitzler P, et al. Evidence for infection with chlamydia pneumoniae in a subgroup of patients with multiple sclerosis. Annals of Neurology. 2000; 47 (5):652-655 - 88.
Bagos PG, Nikolopoulos G, Ioannidis A. Chlamydia pneumoniae infection and the risk of multiple sclerosis: A meta-analysis. Multiple Sclerosis. 2006; 12 (4):397-411 - 89.
Boman J, Roblin PM, Sundström P, Sandström M, Hammerschlag MR. Failure to detect chlamydia pneumoniae in the central nervous system of patients with MS. Neurology. 2000; 54 (1):265 - 90.
Hammerschlag MR, Ke Z, Lu F, Roblin P, Boman J, Kalman B. Is chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis? Journal of Clinical Microbiology. 2000; 38 (11):4274-4276 - 91.
Dong-Si T, Weber J, Liu YB, Buhmann C, Bauer H, Bendl C, et al. Increased prevalence of and gene transcription by chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. Journal of Neurology. 2004; 251 (5):542-547 - 92.
Contini C, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Chlamydophila pneumoniae DNA and mRNA transcript levels in peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Research. 2008; 62 (1):58-61 - 93.
Kaufman M, Gaydos CA, Sriram S, Boman J, Tondella ML, Norton HJ. Is chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Multiple Sclerosis. 2002; 8 (4):289-294 - 94.
Sriram S, Yi YS, Stratton C, Calabresi P, Mitchell W, Ikejima H, et al. Comparative study of the presence of chlamydia pneumoniae in cerebrospinal fluid of patients with clinically definite and monosymptomatic multiple sclerosis. Clinical and Diagnostic Laboratory Immunology. 2002; 9 (6):1332-1337 - 95.
Hao Q , Miyashita N, Matsui M, Wang HY, Matsushima T, Saida T. Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis. Multiple Sclerosis. 2002; 8 (5):436-440 - 96.
Grimaldi LME, Pincherle A, Martinelli-Boneschi F, Filippi M, Patti F, Reggio A, et al. An MRI study of chlamydia pneumoniae infection in Italian multiple sclerosis patients. Multiple Sclerosis. 2003; 9 (5):467-471 - 97.
Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Cerebrospinal fluid molecular demonstration of chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis. 2004; 10 (4):360-369 - 98.
Fainardi E, Castellazzi M, Casetta I, Cultrera R, Vaghi L, Granieri E, et al. Intrathecal production of chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms. Journal of the Neurological Sciences. 2004; 217 (2):181-188 - 99.
Sriram S, Ljunggren-Rose A, Yao SY, Whetsell WO. Detection of chlamydial bodies and antigens in the central nervous system of patients with multiple sclerosis. Journal of Infectious Diseases. 2005; 192 (7):1219-1228 - 100.
Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Annals of Neurology. 2004; 55 :756 - 101.
Sriram S, Yao SY, Stratton C, Moses H, Narayana PA, Wolinsky JS. Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS. Journal of the Neurological Sciences. 2005; 234 (1-2):87-91 - 102.
Contini C, Seraceni S, Cultrera R, Castellazzi M, Granieri E, Fainardi E. Molecular detection of Parachlamydia-like organisms in cerebrospinal fluid of patients with multiple sclerosis. Multiple Sclerosis. 2008; 14 (4):564-566 - 103.
Gilden DH, Devlin ME, Burgoon MP, Owens GP. The search for virus in multiple sclerosis brain. Multiple Sclerosis. Vol. 2. Houndmills, Basingstoke, England; 1996; 2 (4):179-183 - 104.
Dolei A. MSRV/HERV-W/syncytin and its linkage to multiple sclerosis: The usability and the hazard of a human endogenous retrovirus. Journal of Neurovirology. 2005; 11 (2):232-235 - 105.
Keefover RW. The clinical epidemiology of Alzheimer’s disease. Neurologic Clinics. 1996; 14 (2):337-351 - 106.
Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer’s disease: The Baltimore longitudinal study of aging. Neurology. 2000; 54 (11):2072-2077 - 107.
di Carlo A, Baldereschi M, Amaducci L, Lepore V, Bracco L, Maggi S, et al. Incidence of dementia, Alzheimer’s disease, and vascular dementia in Italy. The ILSA study. Journal of the American Geriatrics Society. 2002; 50 (1):41-48 - 108.
Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Incidence and etiology of dementia in a large elderly Italian population. Neurology. 2005; 64 (9):1525-1530 - 109.
Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health. 1998; 88 (9):1337-1342 - 110.
Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. Journal of Neuropathology and Experimental Neurology. 1996; 55 (10):1083-1088 - 111.
Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet. 1997; 349 (9047):241-244 - 112.
Itzhaki RF, Dobson CB, Lin WR, Wozniak MA. Association of HSV1 and apolipoprotein E-ε4 in Alzheimer’s disease. Journal of NeuroVirology. 2001; 7 :570-571 - 113.
Pogo BGT. A study of viral genomes and antigens in brains of patients with alzheimer’s disease. Brain. 1987; 110 (4):907-915 - 114.
Friedland RP, May C, Dahlberg J. The viral hypothesis of Alzheimer’s disease: Absence of antibodies to lentiviruses. Archives of Neurology. 1990; 47 (2):177-178 - 115.
Renvoize EB, Awad LO, Hambling MH. A sero-epidemiological study of conventional infectious agents in alzheimer’s disease. Age and Ageing. 1987; 16 (5):311-314 - 116.
Miklossy J. Alzheimer’s disease--a spirochetosis? Neuroreport. 1993; 4 :841-848 - 117.
Balin BJ, Appelt DM. Role of infection in Alzheimer’s disease. Journal of the American Osteopathic Association. 2001; 101 (12 Suppl Pt 1):1-6 - 118.
Robinson SR, Dobson C, Lyons J. Challenges and directions for the pathogen hypothesis of Alzheimer’s disease. Neurobiology of Aging. 2004; 25 (5):629-637 - 119.
Gérard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ, et al. Chlamydophila (chlamydia) pneumoniae in the Alzheimer’s brain. FEMS Immunology and Medical Microbiology. 2006; 48 (3):355-366 - 120.
Dreses-Werringloer U, Bhuiyan M, Zhao Y, Gérard HC, Whittum-Hudson JA, Hudson AP. Initial characterization of Chlamydophila (chlamydia) pneumoniae cultured from the late-onset Alzheimer brain. International Journal of Medical Microbiology. 2009; 299 (3):187-201 - 121.
Gérard HC, Wang GF, Balin BJ, Schumacher HR, Hudson AP. Frequency of apolipoprotein E (APOE) allele types in patients with chlamydia-associated arthritis and other arthritides. Microbial Pathogenesis. 1999; 26 (1):35-43 - 122.
Gérard HC, Wildt KL, Whittum-Hudson JA, Lai Z, Ager J, Hudson AP. The load of chlamydia pneumoniae in the Alzheimer’s brain varies with APOE genotype. Microbial Pathogenesis. 2005; 39 (1-2):19-26 - 123.
Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiology of Aging. 2004; 25 (4):419-429 - 124.
Apfalter P, Assadian O, Blasi F, Boman J, Gaydos CA, Kundi M, et al. Reliability of nested PCR for detection of chlamydia pneumoniae DNA in atheromas: Results from a multicenter study applying standardized protocols. Journal of Clinical Microbiology. 2002; 40 (12):4428-4434 - 125.
Chacko A, Delbaz A, Walkden H, Basu S, Armitage CW, Eindorf T, et al. Chlamydia pneumoniae can infect the central nervous system via the olfactory and trigeminal nerves and contributes to Alzheimer’s disease risk. Scientific Reports. 2022; 12 (1):2759 - 126.
Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease. Journal of the American Geriatrics Society. 2004; 52 (3):381-387 - 127.
Finefrock AE, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer’s disease. Journal of the American Geriatrics Society. 2003; 51 :1143-1148 - 128.
Cahoon L. The curious case of clioquinol. Nature Medicine. 2009; 15 (4):356-359 - 129.
Contini C, Fainardi E, Seraceni S, Granieri E, Castellazzi M, Cultrera R. Molecular identification and antibody testing of Chlamydophila pneumoniae in a subgroup of patients with HIV-associated dementia complex. Preliminary results. Journal of Neuroimmunology. 2003; 136 (1-2) - 130.
Gartner S. HIV infection and dementia. Science. 2000; 287 - 131.
Airas L, Kotilainen P, Vainionpää R, Marttila RJ. Encephalitis associated with chlamydia pneumoniae. Neurology. 2001; 56 :12 - 132.
Heick A, Skriver E. Chlamydia pneumoniae-associated ADEM. European Journal of Neurology. 2000; 7 :4 - 133.
Contini C. International conference on chlamydial and mycoplasma human infections. Future Microbiology. 2007; 7 - 134.
Tang YW, Sriram S, Li H, Yao SY, Meng S, Mitchell WM, et al. Qualitative and quantitative detection of Chlamydophila pneumoniae DNA in cerebrospinal fluid from multiple sclerosis patients and controls. PLoS One. 2009; 4 (4)